- OLINVYK, oliceridine, is Trevena's first approved drug and offers a compelling safety, efficacy, and economic profile versus IV morphine.
- Revenue growth looks particularly strong, with the potential for triple-digit growth rates in a multi-billion dollar market opportunity.
- Valuation has cut in half following approval, as the market doesn't look to be placing as much value on the market share and revenue growth of OLINVYK.
- Projected FY23 revenues at ~$80 million and forward EV/revenue multiples near sector medians give nearly 250% upside potential.
- Small-cap biotech investing is inherently risky, and clinical trial durations/failures, dilution, and opioid regulation are key risks to Trevena.
For further details see:
Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles